

Abteilung "Experimentelle und klinische Neuroimmunologie" im IMSF

Journalbeiträge

1. Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, Hanke T, Hünig T, Kerkau T, Gold R (2005) Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. *J EXP MED*, 202(3): 445-55.
2. Chuang WY, Ströbel P, Gold R, Nix W, Schalke B, Kiefer R, Opitz A, Klinker E, Müller-Hermelink HK, Marx A (2005) A CTLA4^{high} genotype is associated with myasthenia gravis in thymoma patients. *ANN NEUROL*, 58(4): 644-8.
3. Gold R (2005) Overcoming failure to repair demyelination in EAE: an important step towards neuroprotection in multiple sclerosis. *J NEUROIMMUNOL*, 170(1-2): 1-2.
4. Gold R, Hartung HP (2005) Towards individualised multiple-sclerosis therapy. *LANCET NEUROL*, 4(11): 693-4.
5. Gold R, Bayas A, Toyka KV (2005) [Autoimmune neuropathies - current aspects of immunopathologic diagnostics and therapy]. *NERVENARZT*, 76(8): 1009-21; quiz 1022-3.
6. Gold R, Rieckmann P, Chang P, Abdalla J, PRISMS Study Group (2005) The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. *EUR J NEUROL*, 12(8): 649-56.
7. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R (2005) Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. *CELL IMMUNOL*, 237(2): 123-30.
8. Hofstetter HH, Mössner R, Lesch KP, Linker RA, Toyka KV, Gold R (2005) Absence of reuptake of serotonin influences susceptibility to clinical autoimmune disease and neuroantigen-specific interferon-gamma production in mouse EAE. *CLIN EXP IMMUNOL*, 142(1): 39-44.
9. Ibrahim SM, Gold R (2005) Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? *CURR OPIN NEUROL*, 18(3): 231-5.
10. Linker RA, Rott E, Hofstetter HH, Hanke T, Toyka KV, Gold R (2005) EAE in beta-2 microglobulin-deficient mice: axonal damage is not dependent on MHC-I restricted immune responses. *NEUROBIOL DIS*, 19(1-2): 218-28.
11. Linker RA, Sendtner M, Gold R (2005) Mechanisms of axonal degeneration in EAE--lessons from CNTF and MHC I knockout mice. *J NEUROL SCI*, 233(1-2): 167-72.
12. Linker RA, Stadelmann C, Diem R, Bähr M, Brück W, Gold R (2005) [Recent advances in pathogenesis and therapy of multiple sclerosis]. *FORTSCHR NEUROL PSYC*, 73(12): 715-27.
13. Reinhardt M, Hauff P, Linker RA, Briel A, Gold R, Rieckmann P, Becker G, Toyka KV, Mäurer M, Schirner M (2005) Ultrasound derived imaging and quantification of cell adhesion molecules in experimental autoimmune encephalomyelitis (EAE) by Sensitive Particle Acoustic Quantification (SPAQ). *NEUROIMAGE*, 27(2): 267-78.
14. Schneider-Gold C, Bahr M, Gold R (2005) Mycophenolate mofetil: A new therapeutic option in neuroimmunological diseases. *AKTUEL NEUROL*, 32(8): 477-80.
15. Siglienti I, Bendszus M, Kleinschnitz C, Stoll G (2005) Cytokine profile of iron-laden macrophages: Implications for cellular magnetic resonance imaging. *J NEUROIMMUNOL*, 173(1-2): 166-73. Epub 2005 Dec 27.
16. Sommer C, Weishaupt A, Brinkhoff J, Biko L, Wessig C, Gold R, Toyka KV (2005) Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. *LANCET*, 365(9468): 1406-11.
17. Song IH, Gold R, Straub RH, Burmester GR, Buttgereit F (2005) New glucocorticoids on the horizon: repress, don't activate! *J RHEUMATOL*, 32(7): 1199-1207.
18. Stangel M, Gold R (2005) Intravenous Immunoglobulins in MS. *Int MS J*, 12(1): 5-10, 4.
19. Stangel M, Gold R (2005) [High-dose intravenous immunoglobulins in the treatment of multiple sclerosis. An update]. *NERVENARZT*, 76(10): 1267, 1269-70, 1272.
20. Uttner I, Müller S, Zinser C, Maier M, Süßmuth S, Claus A, Ostermann B, Elitok E, Ecker D, Brettschneider J, Gold R, Tumani H (2005) Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. *NEUROLOGY*, 64(11): 1971-3.
21. Vogler S, Goedde R, Mitterski B, Gold R, Kroner A, Koczan D, Zettl UK, Rieckmann P, Epplen JT, Ibrahim SM (2005) Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. *J MOL MED-JMM*, 83(10): 806-11.

Abteilung "Experimentelle und klinische Neuroimmunologie" im IMSF

Buchbeiträge

1. Bayas A, Gold R (2005) Möglichkeiten und Bedeutung neuroimmunologischer Diagnostik. In: Wallesch CW (Hg.) Neurologie. Urban & Fischer Verlag, München, 135-44.
2. Bayas A, Gold R (2005) Entzündliche Polyneuropathien. In: Wallesch CW (Hg.) Neurologie. Urban & Fischer Verlag, München, 755-76.
3. Gold R, Toyka KV (2005) Erkrankung der neuromuskulären Übertragung. In: Wallesch CW (Hg.) Neurologie. Urban & Fischer Verlag, München, 841-8.
4. Gold R, Kieseier BC, Hartung HP (2005) Immunological properties of the peripheral nervous system. In: Antel J, Birnbaum G, Hartung HP, Vincent A (Hg.) Clinical Neuroimmunology. Oxford University Press, New York, 77-86.
5. Reiners K, Gold R (2005) Polyneuropathien. In: Steinbeck G, Paumgartner G (Hg.) Therapie innerer Krankheiten. Springer Verlag, Heidelberg, 1446-59.